FAPI PET/CT在肝脏恶性肿瘤诊断中的研究进展

Research progress of FAPI PET/CT in the diagnosis of malignant liver tumors

肝脏恶性肿瘤具有高发病率和高病死率,通过相关检查及时获悉肿瘤的进展情况,对其后续诊疗及提高患者五年生存率意义重大。各种同位素标记的成纤维细胞活化蛋白抑制剂广泛用于临床研究,其在肝脏组织中摄取较低且肿瘤/本底比较高,能更好地显示肝脏恶性肿瘤的原发病灶及肝内转移灶,为肝脏恶性肿瘤的早期诊断、精确分期以及放射性核素治疗提供了一种新的方法。基于此背景,现对成纤维激活蛋白抑制剂在肝脏恶性肿瘤诊断中的研究进展进行综述。

Malignant liver tumors have a high incidence and mortality rate.Therefore,it is of great significance to promptly learn about tumor advancement status through relevant examinations for patients'follow-up,diagnosis,and therapy as well as the improvement of the five-year survival rate.The primary lesions and intrahepatic metastases of malignant liver tumors have been better demonstrated in the clinical study with the use of various isotope-labeled fibroblast activating protein inhibitors because of their low uptake in liver tissues and high tumor/background ratio,which provides a new method for early diagnosis,precise staging,and radionuclide therapy.In light of this context,a review of the research progress of fibroblast-activating protein inhibitors for the diagnosis of liver malignant tumors is presented.